Microinvasive glaucoma surgery (MIGS) refers to a new group of surgical procedures which are characterized by the following features: high safety profile, minimal trauma, at least moderate efficacy, ease of use and rapid recovery. The implantation of MIGS devices has increased significantly in the last few years, with several devices obtaining the Conformité Européene mark (iStent trabecular microbypass stent, XEN-45 implant, Hydrus and Cypass) and the United States Food and Drug Administration approval (iStent trabecular microbypass stent) approval. The high safety profile of MIGS allows it to be used earlier than conventional glaucoma surgeries within the glaucoma treatment algorithm, and it is typically combined with cataract surgery in patients with mild-to-moderate primary open angle glaucoma. Other indications for MIGS, the efficacy of MIGS as a solo procedure, and prognostic factors for success after MIGS implantation remain to be determined.

We invite investigators to contribute original research papers which will enhance our understanding of MIGS, its surgical outcomes, and how it compares with other glaucoma treatment modalities.

Potential topics include but are not limited to the following:

• Efficacy of MIGS devices implanted as solo procedures
• Comparative studies between MIGS devices and other treatment options for glaucoma, for example, glaucoma medications, cataract surgery alone, and trabeculectomy
• Pilot studies relevant to the implantation of MIGS devices for indications other than mild-to-moderate primary open angle glaucoma
• Studies investigating prognostic factors for success after MIGS
• Imaging of MIGS devices after implantation and correlation with surgical outcomes
• Complications associated with MIGS devices and management strategies
• Laboratory-based microfluidic or histological studies involving MIGS devices
• Health services and systems research on MIGS devices, including studies on cost-effectiveness and quality of life